Once Daily Valacyclovir for Reducing Viral Shedding in Subjects Newly Diagnosed with Genital Herpes by Martens, Mark G. et al.
Hindawi Publishing Corporation
Infectious Diseases in Obstetrics and Gynecology
Volume 2009, Article ID 105376, 7 pages
doi:10.1155/2009/105376
Clinical Study
OnceDaily ValacyclovirforReducingViral Sheddingin
SubjectsNewlyDiagnosedwithGenital Herpes
Mark G. Martens,1 KennethH.Fife,2 Peter A. Leone,3 Lynn P. Dix,4 andClareA. Brennan4
1Planned Parenthood of Arkansas and Eastern Oklahoma, Inc., 5780 S. Peoria Ave, Tulsa, OK 74105, USA
2Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN 46202, USA
3Division of Infections Diseases, University of North Carolina, Chapel Hill, NC 27599, USA
4GlaxoSmithKline, Research Triangle Park, NC 27709, USA
Correspondence should be addressed to Mark G. Martens, mgmartens@aol.com
Received 26 March 2009; Accepted 17 June 2009
Recommended by Jane R. Schwebke
Objective. Genital herpes (GH) recurrences and viral shedding are more frequent in the ﬁrst year after initial HSV-2 infection.
The objective of this study was to provide the ﬁrst evaluation of valacyclovir 1g once daily compared to placebo in reducing viral
shedding in subjects newly diagnosed with GH. Methods. 70 subjects were randomized to receive valacyclovir 1g daily or placebo
in a crossover design for 60 days with a 7-day washout period. A daily swab of the genital/anal-rectal area was self-collected for
HSV-2 detection by PCR. Subjects attended the clinic for routine study visits and GH recurrence visits. Treatment diﬀerences were
assessedusinganonparametriccrossoveranalysis.Results.52subjectshadatleastonePCRmeasurementinbothtreatmentperiods
and comprised the primary eﬃcacy population. Valacyclovir signiﬁcantly reduced HSV-2 shedding during all days compared to
placebo (mean 2.9% versus 13.5% of all days (P<. 01), a 78% reduction). Valacyclovir signiﬁcantly reduced subclinical HSV-2
shedding during all days compared to placebo (mean 2.4% versus 11.0% of all days (P<. 01), a 78% reduction). However, 79% of
subjects had no GH recurrences while receiving valacyclovir compared to 52% of subjects receiving placebo (P<. 01). Conclusion.
In this study, the frequency of total and subclinical HSV-2 shedding was greater than reported in earlier studies involving subjects
with a history of symptomatic genital recurrences. Our study is the ﬁrst to demonstrate a signiﬁcant reduction in viral shedding
with valacyclovir 1g daily compared to placebo in a population of subjects newly diagnosed with HSV-2 infection.
Copyright © 2009 Mark G. Martens et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Genital herpes is most commonly caused by infection with
herpes simplex virus type 2 (HSV-2), and is one of the most
prevalent sexually transmitted diseases (STD) worldwide [1–
3]. The incidence of new infections is about 1 million cases
per year in the United States [4]. At least 50 million persons
in the United States have HSV-2 infection [5]. However, 86%
of these individuals are unaware of their diagnosis, either
because they do not have symptoms or because they have
symptoms that go unrecognized [3, 6].
Previous studies demonstrated both viral shedding and
recurrences are more frequent in the ﬁrst year after initial
HSV-2infection[7–11].Inonenaturalhistorystudy,women
who acquired genital herpes within a year before enrollment
had more frequent shedding compared to women who had
been infected for one year or more [8]. Another study
found that individuals diagnosed for ≤6 months were
twice as likely to shed asymptomatically compared to those
diagnosed for more than 6 months [11]. Collectively, higher
viral shedding and recurrence rates in subjects with newly
acquired infection may translate to an increased risk of
transmitting virus to uninfected sex partners.
In studies of immunocompetent adults with a known
recurrence pattern, HSV-2 DNA as detected by polymerase
chain reaction (PCR) testing was present on approximately
10% of days [12, 13]. Several investigations have supported
the eﬀect of suppressive antiviral therapy on the reduction
of viral shedding in patients with an established recurrence
pattern [9, 11, 14–17]. More recent studies have shown that
suppressive antiviral therapy is as eﬀective at controlling
symptomatic disease in recently infected persons as it is2 Infectious Diseases in Obstetrics and Gynecology
in those with prevalent infection [18, 19]. Because clinical
and subclinical reactivation of HSV may result in the sexual
transmission of HSV to a partner, suppressing viral shedding
is important at both the individual and population level
[12]. The current study was conducted to provide additional
naturalhistorydatainindividualswhohavebeengivenanew
diagnosisofgenitalherpes,andtoprovidetheﬁrstevaluation
of the eﬃcacy of valacyclovir 1g once daily in reducing HSV-
2 shedding in this population.
2.MaterialsandMethods
2.1. Design. This was a double-blind, randomized, multi-
center, two-way crossover study conducted at 14 centers in
the United States (US) between February and November
2006. Subjects were randomized to receive valacyclovir 1g
or matching placebo once daily for 60 days in each of two
treatment periods in a two-way crossover design. In our
study, the term VAL-PBO is used to describe the treatment
order for subjects randomized to receive valacyclovir in the
ﬁrst treatment period followed by placebo in the second
treatment period; the term PBO-VAL is used to describe the
treatment order for subjects randomized to receive placebo
in the ﬁrst treatment period followed by valacyclovir in
the second treatment period. There was a washout period
of seven days between treatment periods. The 1g dose
of valacyclovir was selected to optimize treatment in this
population, 20% of whom would be expected to have 10
or more outbreaks per year based on previous studies
[7]. The primary endpoint was the percent of all days
with any HSV-2 viral shedding over 60 days deﬁned, for
each subject as the percent of all days with PCR data for
which HSV-2 shedding was detected by a positive PCR
result. Secondary endpoints included percent of all days
with subclinical shedding (without a genital lesion), percent
of all days with clinical shedding (with a genital lesion),
proportion of subjects with no shedding, proportion of
subjects with at least one symptomatic recurrence and time
to ﬁrst symptomatic herpes recurrence.
2.2. Study Population. Eligible subjects were diagnosed with
a ﬁrst recognized episode of herpes at the screening visit or
within 4 months of randomization. Subjects were required
to have documented signs and symptoms of genital HSV-
2 infection, as well as laboratory conﬁrmation (positive
culture, PCR, or type-speciﬁc serology) of HSV-2 infection
to be eligible for the study. Subjects that were enrolled on the
basis of a positive culture/PCR, but in the absence of HSV-
2 antibodies, represented true incident HSV-2 infection. It
was accepted that a subject’s ﬁrst recognized episode of
genital herpes might not represent new infection as prior
episodes may have escaped detection. All subjects signed
an informed consent document approved by an appropriate
review committee prior to any study procedures.
2.3. Procedures. A subject’s participation in the study
included a screening evaluation, a randomization visit,
and eight study visits (four visits per treatment period,
with a 15-day interval between each visit). HSV-1 and
HSV-2 type-speciﬁc serologic testing was conducted at the
screening visit. Immunocompromised subjects, and subjects
seropositive for HIV, were excluded. Subjects were not tested
for HIV infection at baseline. Once randomized, subjects
attended the clinic for additional visits if they suspected
they had a genital herpes recurrence. A genital examination
was conducted at the screening visit for subjects who
presented with genital herpes signs or symptoms. Genital
examinations also were conducted at the randomization
and genital herpes recurrence visits for all subjects. During
each 60-day treatment period and during washout, subjects
collected a single daily swab from their genital/anal-rectal
area for HSV-2 detection by PCR. On Day 1 of a genital
herpes recurrence, swabs of the lesion also were collected
in the clinic for HSV-2 detection by culture and PCR.
During a documented recurrence, a subject temporar-
ily discontinued blinded study medication and received
open-label episodic treatment with valacyclovir 500mg
twice daily for 3 days, after which double-blind therapy
resumed.
Subjects used a telephonic, interactive voice response
systemdailytocaptureinformationongenitallesions,genital
symptoms, and oral outbreaks. Adverse events, concomitant
medications, and treatment compliance information were
collected at each clinic visit, based on recall and discussion
with the subject as well as pill counts. Blood and urine
samples were collected for hematology, clinical chemistry,
and urinalysis at the screening visit and at the end of
each treatment period. Pregnancy testing was performed at
baseline and at the end of each treatment period.
2.4. Laboratory Methods. The HerpeSelect ELISA glycopro-
tein G-based assay (Focus Diagnostics, Cypress, Calif, USA)
was used to detect the presence of HSV-1 and HSV-2
antibodies at screen (Quest Diagnostics, Van Nuys, Calif,
USA). Samples demonstrating an index value >1.1 were
considered positive. No conﬁrmatory testing was performed.
Viral isolates from cultures were conﬁrmed and typed with
monoclonal antibodies at Quest Diagnostics. HSV-2 DNA
was assessed by qualitative ﬂorescent-based real time PCR
assay at the University of Washington Virology Research
Laboratory, Seattle, Wash, USA [20].
2.5. Statistical Analyses. In this study, it was estimated that
47 completed subjects provided at least 90% power to detect
a reduction in the mean percent days of HSV-2 shedding
from 9.6% in the placebo treatment phase to 2.8% in the
valacyclovir treatment phase, assuming standard deviations
of 9.8% and 5.6%, respectively, and a correlation of 0.4.
This study also was powered for the secondary endpoint
of subclinical shedding. Forty-seven completed subjects
provided 90% power to detect a reduction in the mean
percent days of subclinical HSV-2 shedding from 7.0% in
the placebo treatment phase to 2.8% in the valacyclovir
treatment phase, assuming standard deviations of 9.3% and
5.4%, respectively, and a correlation of 0.4. To allow for
dropouts, a sample size of 66 subjects was chosen.Infectious Diseases in Obstetrics and Gynecology 3
The populations considered in the overall analysis
included the Intent-to-Treat (ITT) exposed, consisting of all
subjects who received at least one dose of investigational
product. This was the primary population for assessing
safety. Also considered was the Intent-to-Treat Crossover
(ITTC) population consisting of all ITT subjects who had at
least one PCR result in each treatment period. This was the
primary population for assessing eﬃcacy. The First Period
Eﬃcacypopulationconsistedofallpatientswitheﬃcacydata
in the ITT-Exposed, with the exception of 2 subjects whose
data was compromised (see Section 3). This was the primary
populationforassessingeﬃcacyintheﬁrsttreatmentperiod.
The treatment comparison for continuous endpoints,
including the primary endpoint, was tested using nonpara-
metric crossover analysis methods in the ITTC population
[21]. The test of treatment diﬀerence was preceded by a test
of carryover eﬀect using a Wilcoxon rank-sum test at the 5%
level of signiﬁcance [21]. If this test was signiﬁcant, then the
treatmentcomparisonwouldbetestedusingTheFirstPeriod
Eﬃcacy population only. This analysis was carried out as a
supporting analysis in any case because the test of carryover
may have relatively low power.
The binomial secondary endpoints were analyzed using
Prescott’s method [22]. Time to ﬁrst genital recurrence
was evaluated with Kaplan-Meier estimates and log-rank
test using the First Period Eﬃcacy population and data
in treatment period 1. The reported safety measures were
adverse events and laboratory data.
3. Results
3.1. Subject Characteristics. Seventy subjects from 14 centers
in the United States were randomized into the study, 35
subjectstotheVAL-PBOtreatmentsequence,and35subjects
to the PBO-VAL treatment sequence. During the course
of routine monitoring, errors in sample identiﬁcation were
discovered for two subjects at one site. The error was felt
to compromise the integrity of the data; therefore, swab
samples from two subjects in the VAL-PBO sequence group
were excluded from the eﬃcacy analysis. An additional three
subjects were “lost to follow-up” early in treatment period
1. These three subjects had some swabbing samples but all
PCR assay results were missing, leaving 65 subjects in the
First Period Eﬃcacy population.
Twenty of the 70 (29%) subjects in the ITT population
prematurely withdrew from the study (11 while receiving
valacyclovir, 9 while receiving placebo). The primary reason
for withdrawal was “lost to followup” (n = 8, 11%), followed
by“otherreason”(n = 6,9%),“subjectdecidedtowithdraw”
(n = 4, 6%), and adverse event (n = 2, 3%). At least
one major protocol deviation was recorded for 35 (50%)
subjects randomized. Deviations included failure to take at
least 80% of double-blind study medication (n = 13, 37%)
and genital/anal-rectal swab PCR results on fewer than 85%
of study days (n = 20, 57%).
The study population was predominantly female (70%);
51% were white (Table 1). Of the 70 subjects randomized,
9 (13%) were HSV-2 seronegative at entry indicating newly
Table 1: Demographics ITT Population.
Demographics VAL-Placebo Placebo-VAL
No. of subjects 35 35
Female gender, n (%) 22 (63) 27 (77)
Mean Age, years (SD),
range
29 (9), 18–49 33 (10), 20–58
White, n (%) 19 (54) 17 (49)
Black, n (%) 13 (37) 15 (43)
HSV-1a and HSV-2
Antibody Positive, n (%)
17 (49) 19 (54)
HSV-1 Antibody Positive,
HSV-2 Antibody Negative,
n (%)
2( 6 ) 1( 3 )
HSV-1 Antibody Negative,
HSV-2 Antibody Positive,
n (%)
13 (37) 12 (34)
HSV-1 and HSV-2
Antibody Negative, n (%)
3( 9 ) 3( 9 )
aOne patient in each treatment group had an HSV-1 equivocal result and
are included here.
acquired HSV-2 infection. Note that one of these 9 subjects
did not have eﬃcacy data in treatment period 1. Of the 8
in the First Period Eﬃcacy population, 6 were also HSV-
1 negative, indicating primary infection. All nine subjects
presented with laboratory conﬁrmation of HSV-2 infection
by culture or PCR at screen or upon initial diagnosis made
within 4 months of randomization. These subjects represent
a subset of the population who had a clearly documented
recent HSV-2 infection.
3.2. Viral Shedding. The primary eﬃcacy endpoint was the
diﬀerence in mean percent of all days with HSV-2 shedding
as determined by a type-speciﬁc HSV PCR assay. For the
ITTC population, shedding was reported on a mean 13.5%
of all days in subjects while receiving placebo compared to a
mean 2.9% of days in subjects while receiving valacyclovir
(P<. 001), a signiﬁcant decrease representing a 78%
reduction in total HSV-2 shedding (Table 2). The test of
period diﬀerences as well as the test of residuals (carryover
eﬀect) was not signiﬁcant, P = .362 and P = .401,
respectively. The supporting analysis of total days with
shedding during treatment period 1 was consistent with the
twoperiod carryover analysis. In the ﬁrst treatment period,
there was a statistically signiﬁcant (83%) reduction in total
days with shedding (Table 2).
The mean percent of all days with subclinical HSV-2
shedding was a secondary endpoint (Table 2). In the ITTC
population, subclinical shedding was identiﬁed on a mean
11% of days in subjects while receiving placebo compared to
a mean 2.4% of days in subjects while receiving valacyclovir
(P<. 001), a signiﬁcant decrease representing a 78%
reduction in subclinical shedding. Signiﬁcant diﬀerences
between valacyclovir and placebo also were demonstrated
in the percent of days with clinical shedding, proportion of4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Percent of Days with HSV-2 Viral Shedding.
Population ITTC Valacyclovir Placebo P-value % Reduction
(n = 52) (n = 52)
Period 1
n 25 27
Mean (SD %) 3.0 (4.6) 14.3 (16.6)
Range 0–17 0–68
Period 2
n 27 25
Mean (SD %) 2.9 (6.5) 12.6 (17.4)
Range 0–29 0–61
Overall
n 52 52
Mean (SD %) 2.9 (5.6) 13.5 (16.9) <. 001 78
Range 0–29 0–68
ITT Period 1 n 30 35 <. 001 83
Mean (SD %) 2.6 (4.3) 14.9 (18.3)
Other Eﬃcacy Parameters
ITTC Valacyclovir (n = 52) Placebo (n = 52) P-value
Percent days with subclinical shedding,
Mean (SD %)
2.4 (4.8) 11 (15.1) <.001
Percent days with clinical shedding, Mean
(SD %)
0.6 (1.7) 2.4 (4.4) .014
Subjects with no Shedding, n (%) 31 (60) 15 (29) <.001
Proportion of subjects recurrencefree, n (%) 41 (79) 27 (52) .003
Median time to ﬁrst genital herpes
recurrencea (days)
>68 61 .010
aFirst treatment period.
subjects with no shedding, proportion of subjects with no
recurrences, and time to ﬁrst recurrence (Table 2).
Valacyclovir1goncedailywaswelltolerated,withsimilar
adverse event reporting compared to placebo. Two subjects
withdrew from the study because of adverse events during
treatment period 1 and did not progress to treatment period
2. One subject receiving placebo experienced a headache of
moderate intensity; a second subject receiving valacyclovir
experienced elevated alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) that were felt to be related
to a concomitant medication. Both subjects withdrew with-
out breaking the study blind and the relationship of the
adverse event to the study drug was made while the drug was
still blinded.
A post-hoc analysis of the 8 subjects with documented
incident HSV-2 infection was conducted to explore shedding
and recurrence rates in this subset of participants. In an
analysis of ﬁrst period placebo treatment data, 4 subjects
were HSV-2 seronegative including 3 who were also HSV-1
seronegative (primary infection) and 31 subjects were HSV-
2 seropositive. This analysis suggests that recently infected
subjects in the ﬁrst period placebo group shed HSV-2 more
often than those already with HSV-2 antibody (Table 3 and
Figure 1). In an analysis of ﬁrst period valacyclovir treatment
data, 4 subjects were HSV-2 seronegative (including 3 who
were also HSV-1 seronegative), and 26 subjects were HSV-
2 seropositive. Among subjects who received valacyclovir in
the ﬁrst treatment period, similar results were obtained for
Table 3: Post-hoc Analysis of Patients with Documented Incident
Infection—Results from the First Treatment Period.
HSV-2 Antibody HSV-2 Antibody
Negativea n = 4 Positive n = 31
Percent days with total
shedding, Mean (SD %)
P-valueb
43.8 (18.6 ) 11.2 (14.8)
P<. 001
Percent days with
subclinical shedding, Mean
(SD %) P-valueb
31.9 (12.8 ) 8.9 (14.1)
P = .002
Proportion of subjects
recurrence-freec, n (%)
0 (0) 19 (61)
aThis group includes 3 subjects who were HSV-1 and HSV-2 seronegative,
and one subject who was HSV-1 seropositive and HSV-2 seronegative.
bThis was an exploratory analysis; P-values should be regarded only as a
rough guide to the magnitude of diﬀerences between groups.
cThis diﬀerence was statistically signiﬁcant (P = .04); however, this was an
exploratory analysis.
HSV-2 seronegative and seropositive subjects with respect
to total days with shedding (5.9% versus 2.1%) and the
proportion of subjects recurrence-free (100% versus 81%).
The percentage of days with subclinical shedding was higher
in the HSV-2 seronegative group compared to the HSV-2
seropositive (5.9% versus 1.4%, P = .05); however, the study
was not powered for this comparison.Infectious Diseases in Obstetrics and Gynecology 5
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Figure 1: Scatter plot of shedding data for subjects receiving
placebo in the ﬁrst treatment period. The column labeled HSV-2 +
shows data from subjects whose HSV-2 antibody test was positive at
enrollment(n = 31).Thehorizontallinerepresentsthemeanvalue.
The next column shows the individual values for the 3 subjects who
werenegativeforbothHSV-1andHSV-2antibody;thenextcolumn
shows the one subject who was HSV-1 antibody positive and HSV2
antibody negative at enrollment. (a) Total HSV-2 shedding, and (b)
subclinical shedding.
4. Discussion
The present study is the ﬁrst to evaluate valacyclovir 1g once
daily to reduce HSV-2 viral shedding in a population of
subjects newly diagnosed with genital herpes infection. In
our study, valacyclovir 1g once daily signiﬁcantly reduced
viral shedding by 78% compared to placebo. The eﬀect of
suppressive valacyclovir therapy on reducing viral shedding
and reducing the frequency of genital recurrences is similar
to that reported in earlier studies that enrolled persons with
an established history of genital herpes [12, 13, 18, 19].
Results from a large, randomized, controlled study
demonstrated that valacyclovir suppression (500mg daily)
reduced transmission of symptomatic HSV2 infection by
75% and overall acquisition (HSV-2 seroconversion) by 48%
in discordant couples [12]. Within this trial, a viral shedding
substudy of 89 patients evaluated for 60 days demonstrated
a 73% reduction in total days of viral shedding (mean 2.9%
versus 10.8%, as measured by PCR) and a 64% reduction in
days of subclinical viral shedding (mean 2.8% versus 7.8%)
in infected source partners receiving valacyclovir compared
to those receiving placebo.
In a study of valacyclovir 1g once daily for the reduction
of HSV-2 viral shedding in 152 subjects with a history of ≥6
genital herpes recurrences per year, the mean percent of days
with HSV-2 shedding was 9.3% in the placebo group and
2.7% in the valacyclovir group, a 71% reduction (P<. 001).
The mean percent of subclinical days with shedding was
6.4% on placebo and 2.7% in the valacyclovir group, a 58%
reduction (P<. 001) [13].
In another HSV-2 viral shedding study that enrolled a
heterogeneous population of 69 subjects (newly diagnosed
with HSV-2 infection, and diagnosed >6 months prior to
study entry), participants received oral valacyclovir 500mg
BID, acyclovir 400mg BID, and placebo in random order
for 7 weeks each, in a three-period crossover design [11].
There was a one-week washout between treatment periods.
However, 27 subjects (39%) had a diagnosis of a ﬁrst episode
of genital herpes ≤6 months before randomization. Overall,
for the 69 subjects randomized, HSV DNA was detected by
P C Rf r o ma tl e a s to n ea n a t o m i c a ls i t eo n4 0 . 2 %o ft h ed a y s
while receiving placebo, compared to 8.0% of days while
receiving acyclovir (80% reduction) and 7.2% of days while
receiving valacyclovir (82% reduction).
In the current study, the mean percent of days with
total HSV-2 shedding was 2.9% while receiving valacyclovir,
comparedto13.5%whilereceivingplacebo.Theseresultsare
similar to those of the ﬁrst two studies [12, 13]n o t e da b o v e
except that the proportion of days with shedding while on
placebo wasslightlyhigher in thecurrentstudy. Itis not clear
if that diﬀerence is meaningful, but it could be because our
subjects were recently infected and these persons shed virus
more frequently than those with established disease [8, 9].
The study by Gupta et al. reported rates of shedding in both
theplaceboandtreatmentphasesthatwerehigherthanthose
of the current study. However, the proportional reduction
of shedding in subjects on suppression in our study was
similar to that reported by Gupta et al. The reason for the
discrepancy between the results reported by Gupta et al. and
other studies, including the one reported here, is uncertain,
but could be related to the multiple swab technique used
in the earlier study or in the selection of study subjects
[11].
Of the 70 subjects in this study, 9 (13%) were HSV-
2 seronegative at the time of diagnosis by culture or PCR.
These subjects clearly had new HSV-2 infections while the
remaining study subjects had been infected long enough
to mount an antibody response by the time they enrolled
in the study. This provided us with the opportunity to
explore the diﬀerences in viral shedding between those
with and without antibodies to HSV-2 in the group ran-
domized to placebo treatment in the ﬁrst study period.
As was previously reported in a study that evaluated viral
shedding by culture in initially HSV-2 seronegative subjects
[23], asymptomatic shedding was extremely common. Our6 Infectious Diseases in Obstetrics and Gynecology
post-hoc analysis showed shedding rates 4-to5-fold higher
among those initially HSV-2 seronegative subjects compared
to the broader group of subjects who were newly diagnosed
but already HSV-2 seropositive. Given the limited number of
patients in the HSV-2 seronegative subset, the viral shedding
results in this cohort must be interpreted with caution, yet
the observation suggests the potential importance of early
treatment in persons with new HSV-2 infection.
The CDC advocates the use of suppressive therapy for
reducing genital herpes recurrences in patients with frequent
recurrences (≥6 recurrences/year), and states treatment also
is eﬀective in patients with less frequent recurrences (5).
In addition, sexual transmission of HSV can occur during
asymptomatic periods, and asymptomatic viral shedding is
most frequent during the ﬁrst 12 months after acquiring
HSV-2 (5). Two recent studies have shown that suppressive
therapy with valacyclovir in subjects with newly diagnosed
HSV-2 genital herpes has clinical eﬃcacy in reducing
outbreaks, similar to that seen in persons with established
recurrent disease [18, 19]. The current study extends those
ﬁndings by showing that the impact of suppressive vala-
cyclovir on viral shedding is also similar to that found
in persons with established recurrent genital herpes. Taken
together, these studies suggest that there is no reason to
wait until a person with newly diagnosed genital herpes
establishes a recurrence pattern to consider suppressive
therapy. In fact, because of the high rate of viral shedding
and high probability of clinical recurrences, persons newly
diagnosed with HSV-2 infection may be among the best
candidates for suppressive therapy.
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